|
US5801195A
(en)
*
|
1994-12-30 |
1998-09-01 |
Celgene Corporation |
Immunotherapeutic aryl amides
|
|
DE69624081T2
(de)
*
|
1995-12-20 |
2003-06-12 |
Agouron Pharmaceuticals, Inc. |
Matrix-metalloprotease Inhibitoren
|
|
US6747027B1
(en)
|
1996-07-22 |
2004-06-08 |
Pharmacia Corporation |
Thiol sulfonamide metalloprotease inhibitors
|
|
WO1998005635A1
(en)
*
|
1996-08-07 |
1998-02-12 |
Darwin Discovery Limited |
Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
|
|
US6566384B1
(en)
|
1996-08-07 |
2003-05-20 |
Darwin Discovery Ltd. |
Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
|
|
EA001460B1
(ru)
*
|
1996-09-27 |
2001-04-23 |
Фармация Энд Апджон Компани |
β-СУЛЬФОНИЛ ГИДРОКСАМОВЫЕ КИСЛОТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ МАТРИЧНЫХ МЕТАЛЛОПРОТЕИНАЗ
|
|
US5962481A
(en)
|
1996-10-16 |
1999-10-05 |
American Cyanamid Company |
Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
|
|
US6548524B2
(en)
|
1996-10-16 |
2003-04-15 |
American Cyanamid Company |
Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
|
|
US6228869B1
(en)
|
1996-10-16 |
2001-05-08 |
American Cyanamid Company |
Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
|
|
US5929097A
(en)
*
|
1996-10-16 |
1999-07-27 |
American Cyanamid Company |
Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
|
|
US5977408A
(en)
*
|
1996-10-16 |
1999-11-02 |
American Cyanamid Company |
Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
|
|
AU768182B2
(en)
*
|
1996-12-19 |
2003-12-04 |
Aventis Pharmaceuticals Inc. |
Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and alpha,beta-unsaturated carboxylic acid and aldehyde compounds
|
|
ES2280085T3
(es)
*
|
1996-12-19 |
2007-09-01 |
Aventis Pharmaceuticals Inc |
Procedimiento para la sintesis en fase solida de compuestos de aldehidos, cetonas y acido hidroxamico.
|
|
US6133409A
(en)
*
|
1996-12-19 |
2000-10-17 |
Aventis Pharmaceuticals Products Inc. |
Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and αβ-unsaturated carboxylic acid and aldehyde compounds
|
|
US6392010B1
(en)
|
1996-12-19 |
2002-05-21 |
Aventis Pharmaceuticals Inc. |
Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and αβ-unsaturated carboxylic acid and aldehyde compounds
|
|
ES2238755T3
(es)
*
|
1997-01-22 |
2005-09-01 |
Aventis Pharmaceuticals Inc. |
Acidos beta-tiocarboxilicos sustituidos.
|
|
JP2000507975A
(ja)
*
|
1997-02-07 |
2000-06-27 |
ファイザー・インク |
Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
|
|
DE69823019T2
(de)
*
|
1997-02-27 |
2005-03-31 |
Wyeth Holdings Corp. |
N-hydroxy-2-(alkyl, aryl oder heteroaryl sulfanyl, sulfinyl oder sulfonyl)-3-substituierte alkyl-, aryl- oder heteroarylamide als matrixmetalloproteinaseinhibitoren
|
|
US7115632B1
(en)
|
1999-05-12 |
2006-10-03 |
G. D. Searle & Co. |
Sulfonyl aryl or heteroaryl hydroxamic acid compounds
|
|
US6696449B2
(en)
|
1997-03-04 |
2004-02-24 |
Pharmacia Corporation |
Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
|
|
DE69819878T2
(de)
*
|
1997-03-04 |
2004-04-22 |
Monsanto Co. |
Divalente sulfonyl-aryl-oder heteroaryl hydroxamsäureverbindungen
|
|
US6794511B2
(en)
|
1997-03-04 |
2004-09-21 |
G. D. Searle |
Sulfonyl aryl or heteroaryl hydroxamic acid compounds
|
|
WO1998039326A1
(en)
|
1997-03-04 |
1998-09-11 |
Monsanto Company |
Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
|
|
US6638952B1
(en)
|
1997-03-04 |
2003-10-28 |
Pharmacia Corporation |
Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
|
|
WO1998039316A1
(en)
|
1997-03-04 |
1998-09-11 |
Monsanto Company |
N-hydroxy 4-sulfonyl butanamide compounds
|
|
AUPO721997A0
(en)
*
|
1997-06-06 |
1997-07-03 |
Queensland Institute Of Medical Research, The |
Anticancer compounds
|
|
US6300514B1
(en)
|
1997-06-25 |
2001-10-09 |
Ono Pharmaceutical Co., Ltd. |
Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient
|
|
EP1030665A4
(en)
*
|
1997-10-17 |
2002-11-27 |
Aventis Pharm Prod Inc |
THERAPEUTIC USE OF CHINOLINE DERIVATIVES
|
|
US20010039287A1
(en)
*
|
1997-11-14 |
2001-11-08 |
Thomas E Barta |
Aromatic sulfone hydroxamic acid metalloprotease inhibitor
|
|
US6750228B1
(en)
*
|
1997-11-14 |
2004-06-15 |
Pharmacia Corporation |
Aromatic sulfone hydroxamic acid metalloprotease inhibitor
|
|
EP1042290A1
(en)
*
|
1997-11-14 |
2000-10-11 |
G.D. SEARLE & CO. |
Aromatic sulfone hydroxamic acid metalloprotease inhibitor
|
|
ATE232192T1
(de)
|
1997-11-21 |
2003-02-15 |
Upjohn Co |
Alpha-hydroxy, -amino und -fluoro derivate von beta-sulfonylhydroxamsäuren als matrixmetalloproteinasen-inhibitoren
|
|
US6288063B1
(en)
*
|
1998-05-27 |
2001-09-11 |
Bayer Corporation |
Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
|
|
DK1357109T3
(da)
|
1998-06-18 |
2008-09-08 |
Hoffmann La Roche |
Fremgangsmåde til arylalkylsulfid
|
|
FR2780402B1
(fr)
*
|
1998-06-30 |
2001-04-27 |
Adir |
Nouveaux composes acides carboxyliques et hydroxamiques inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
US6172064B1
(en)
*
|
1998-08-26 |
2001-01-09 |
Glaxo Wellcome Inc. |
Formamides as therapeutic agents
|
|
US6020358A
(en)
*
|
1998-10-30 |
2000-02-01 |
Celgene Corporation |
Substituted phenethylsulfones and method of reducing TNFα levels
|
|
US6358980B1
(en)
*
|
1999-01-27 |
2002-03-19 |
American Cyanamid Company |
Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
|
|
YU57101A
(sh)
|
1999-02-08 |
2005-06-10 |
G.D. Saerle & Co. |
Sulfamat hidroksamična kiselina inhibitor metaloproteaze
|
|
US6800646B1
(en)
|
1999-02-08 |
2004-10-05 |
Pharmacia Corporation |
Sulfamato hydroxamic acid metalloprotease inhibitor
|
|
US6583299B1
(en)
|
1999-05-20 |
2003-06-24 |
G.D. Searle & Co. |
α-amino-β-sulfonyl hydroxamic acid compounds
|
|
US6869951B1
(en)
|
1999-07-16 |
2005-03-22 |
Pharmacia Corporation |
Method of changing conformation of a matrix metalloproteinase
|
|
SI1212089T1
(sl)
|
1999-08-21 |
2006-08-31 |
Altana Pharma Ag |
Sinergisticna kombinacija roflumilasta in salmeterola
|
|
GB9922825D0
(en)
*
|
1999-09-25 |
1999-11-24 |
Smithkline Beecham Biolog |
Medical use
|
|
US6667316B1
(en)
|
1999-11-12 |
2003-12-23 |
Celgene Corporation |
Pharmaceutically active isoindoline derivatives
|
|
GB9929979D0
(en)
*
|
1999-12-17 |
2000-02-09 |
Darwin Discovery Ltd |
Hydroxamic acid derivatives
|
|
US6699899B1
(en)
|
1999-12-21 |
2004-03-02 |
Celgene Corporation |
Substituted acylhydroxamic acids and method of reducing TNFα levels
|
|
US6326388B1
(en)
|
1999-12-21 |
2001-12-04 |
Celgene Corporation |
Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
|
|
US6683093B2
(en)
|
2000-05-12 |
2004-01-27 |
Pharmacia Corporation |
Aromatic sulfone hydroxamic acids and their use as protease inhibitors
|
|
EP1292576A1
(en)
|
2000-05-15 |
2003-03-19 |
Darwin Discovery Limited |
Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
|
|
WO2001087883A1
(en)
*
|
2000-05-15 |
2001-11-22 |
Darwin Discovery Limited |
Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
|
|
FR2809623B1
(fr)
*
|
2000-06-05 |
2003-09-05 |
Sanjuan Benito Arranz |
Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : du sildenafil (ou de ses derives)
|
|
US8030343B2
(en)
|
2000-06-08 |
2011-10-04 |
Celgene Corporation |
Pharmaceutically active isoindoline derivatives
|
|
US8026280B2
(en)
|
2001-03-27 |
2011-09-27 |
Errant Gene Therapeutics, Llc |
Histone deacetylase inhibitors
|
|
US7312247B2
(en)
*
|
2001-03-27 |
2007-12-25 |
Errant Gene Therapeutics, Llc |
Histone deacetylase inhibitors
|
|
US6495719B2
(en)
*
|
2001-03-27 |
2002-12-17 |
Circagen Pharmaceutical |
Histone deacetylase inhibitors
|
|
US7842727B2
(en)
*
|
2001-03-27 |
2010-11-30 |
Errant Gene Therapeutics, Llc |
Histone deacetylase inhibitors
|
|
AP2003002908A0
(en)
|
2001-05-11 |
2003-12-31 |
Pharmacia Corp |
Aromatic sulfone hydroxamates and their use as protease inhibitors
|
|
US6683078B2
(en)
|
2001-07-19 |
2004-01-27 |
Pharmacia Corporation |
Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
|
|
PE20030701A1
(es)
|
2001-12-20 |
2003-08-21 |
Schering Corp |
Compuestos para el tratamiento de trastornos inflamatorios
|
|
TW200406197A
(en)
*
|
2002-04-25 |
2004-05-01 |
Ono Pharmaceutical Co |
Therapelitic agent for inflammatory bowel disease containing hydroxamic acid as effective component
|
|
EP1501827A2
(en)
|
2002-04-25 |
2005-02-02 |
Pharmacia Corporation |
Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acid and their use as protease inhibitors
|
|
EP1511477A4
(en)
*
|
2002-05-22 |
2008-04-09 |
Errant Gene Therapeutics Llc |
HISTONE DEACETYLASE INHIBITORS BASED ON ALPHA-KETO-EPOXYDE COMPOUNDS
|
|
AU2003277878A1
(en)
*
|
2002-06-25 |
2004-01-06 |
Pharmacia Corporation |
Arylsulfonylhydroxamic acid and amide derivatives and their use as protease inhibitors
|
|
AU2003291097A1
(en)
*
|
2002-11-20 |
2004-06-15 |
Errant Gene Therapeutics, Llc |
Treatment of lung cells with histone deacetylase inhibitors
|
|
DE60331367D1
(de)
|
2002-12-30 |
2010-04-01 |
Angiotech Int Ag |
Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
|
|
US7135493B2
(en)
|
2003-01-13 |
2006-11-14 |
Astellas Pharma Inc. |
HDAC inhibitor
|
|
JP2006522151A
(ja)
|
2003-04-01 |
2006-09-28 |
アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ |
不妊症におけるホスホジエステラーゼ阻害剤
|
|
WO2004087042A2
(en)
|
2003-04-04 |
2004-10-14 |
Yeda Research And Development Co. Ltd. |
Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
|
|
US7244759B2
(en)
|
2004-07-28 |
2007-07-17 |
Celgene Corporation |
Isoindoline compounds and methods of making and using the same
|
|
WO2006052916A2
(en)
*
|
2004-11-08 |
2006-05-18 |
Errant Gene Therapeutics, Inc. |
Histone deacetylase inhibitors
|
|
PT1981877E
(pt)
|
2006-02-07 |
2012-05-24 |
Astellas Pharma Inc |
Compostos de n-hidroxiacrilamida
|
|
WO2008147480A2
(en)
*
|
2007-02-01 |
2008-12-04 |
Panthera Biopharna, Llc. |
Hydroxamic acid derivatives of 3-phenyl propionic acids useful as thrapeutic agents for treating anthrax poisoning
|
|
US7879911B2
(en)
|
2007-02-01 |
2011-02-01 |
Johnson Alan T |
Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning
|
|
BRPI0807256A2
(pt)
|
2007-02-23 |
2014-07-22 |
Yeda Res & Dev |
"composição com fórmula geral i, composto com a fórmula ii, anticorpo, método de produção de inibidor de metaloproteinase,composição farmacêutica, método de tratamento de doença associada a atividade incompatível ou anormal de metaloproteinas, método de inibição da atividade da metaloproteinase matriz em uma célula"
|
|
WO2016128131A1
(en)
*
|
2015-02-09 |
2016-08-18 |
National And Kapodistrian University Of Athens |
Beta-lactone inhibitors of phospholipase a2 and uses thereof
|
|
BR112021006407A8
(pt)
|
2018-10-04 |
2022-12-06 |
Inst Nat Sante Rech Med |
uso de inibidores do egfr para ceratodermas
|